

Cover Story
By Matthew Bin Han Ong
In his first talk to NCI staff, director Norman “Ned” Sharpless presented himself as an institute insider—highlighting his career-long relationships with NCI and its “legends,” demonstrating his grasp of the institute's agenda and research portfolio.
In Brief


Drugs & Targets
Trending Stories
- Vinay Prasad’s CV inaccurately claims past membership on the President’s Cancer Panel
- FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients
“Patients are owed another review.” - CDC’s recommendation to delay infant hepatitis B shot is likely to raise infections, JAMA studies show
- Breakthrough Therapy designation, ASCO plenary, and NEJM publication notwithstanding, breast cancer drug camizestrant gets a No from ODAC
- J. Craig Venter’s work was foundational to cancer advancement of the past 25 years
- CBER Director Vinay Prasad dared to “say no to drugs”














